Pediatrix Medical Group (NYSE:MD) Downgraded by StockNews.com to Hold

StockNews.com downgraded shares of Pediatrix Medical Group (NYSE:MD) from a buy rating to a hold rating in a report released on Thursday.

Other equities analysts also recently issued research reports about the company. Truist Financial increased their price target on Pediatrix Medical Group from $13.00 to $16.00 and gave the company a “hold” rating in a report on Monday, November 4th. Mizuho increased their price target on Pediatrix Medical Group from $13.00 to $15.00 and gave the company a “neutral” rating in a report on Tuesday. UBS Group increased their price target on Pediatrix Medical Group from $10.50 to $16.50 and gave the company a “neutral” rating in a report on Tuesday, November 5th. Deutsche Bank Aktiengesellschaft increased their price target on Pediatrix Medical Group from $9.00 to $15.00 and gave the company a “hold” rating in a report on Monday, November 4th. Finally, Jefferies Financial Group increased their price target on Pediatrix Medical Group from $14.00 to $18.00 and gave the company a “buy” rating in a report on Tuesday, November 5th. Five analysts have rated the stock with a hold rating and one has given a buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $16.10.

Pediatrix Medical Group Trading Up 0.4 %

NYSE:MD opened at $14.81 on Thursday. The stock’s 50 day moving average price is $12.84 and its 200 day moving average price is $10.00. Pediatrix Medical Group has a 52 week low of $6.62 and a 52 week high of $16.41. The company has a market capitalization of $1.27 billion, a P/E ratio of -4.82, a P/E/G ratio of 2.08 and a beta of 1.55. The company has a debt-to-equity ratio of 0.83, a quick ratio of 1.42 and a current ratio of 1.42.

Pediatrix Medical Group (NYSE:MD) last announced its earnings results on Friday, November 1st. The company reported $0.44 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.37 by $0.07. Pediatrix Medical Group had a positive return on equity of 12.79% and a negative net margin of 12.65%. The firm had revenue of $511.20 million during the quarter, compared to analysts’ expectations of $498.87 million. During the same quarter in the prior year, the business earned $0.29 earnings per share. The company’s revenue was up .9% on a year-over-year basis. On average, research analysts forecast that Pediatrix Medical Group will post 1.26 EPS for the current fiscal year.

Insider Transactions at Pediatrix Medical Group

In other Pediatrix Medical Group news, Director Laura A. Linynsky sold 7,000 shares of Pediatrix Medical Group stock in a transaction on Tuesday, August 27th. The shares were sold at an average price of $11.16, for a total transaction of $78,120.00. Following the sale, the director now owns 30,805 shares in the company, valued at $343,783.80. The trade was a 18.52 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO James D. Swift sold 11,100 shares of Pediatrix Medical Group stock in a transaction on Friday, August 30th. The stock was sold at an average price of $10.79, for a total transaction of $119,769.00. Following the sale, the chief executive officer now owns 170,001 shares in the company, valued at $1,834,310.79. This represents a 6.13 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 53,808 shares of company stock worth $751,277. Insiders own 2.00% of the company’s stock.

Institutional Investors Weigh In On Pediatrix Medical Group

A number of institutional investors have recently bought and sold shares of the business. Quest Partners LLC boosted its stake in Pediatrix Medical Group by 25.6% during the third quarter. Quest Partners LLC now owns 3,054 shares of the company’s stock worth $35,000 after buying an additional 622 shares in the last quarter. The Manufacturers Life Insurance Company boosted its stake in Pediatrix Medical Group by 3.5% during the second quarter. The Manufacturers Life Insurance Company now owns 32,387 shares of the company’s stock worth $245,000 after buying an additional 1,088 shares in the last quarter. ProShare Advisors LLC boosted its stake in Pediatrix Medical Group by 7.4% during the first quarter. ProShare Advisors LLC now owns 16,937 shares of the company’s stock worth $170,000 after buying an additional 1,167 shares in the last quarter. Nisa Investment Advisors LLC lifted its holdings in shares of Pediatrix Medical Group by 47.2% during the second quarter. Nisa Investment Advisors LLC now owns 4,755 shares of the company’s stock valued at $36,000 after acquiring an additional 1,524 shares during the period. Finally, Quarry LP lifted its holdings in shares of Pediatrix Medical Group by 54.1% during the third quarter. Quarry LP now owns 4,735 shares of the company’s stock valued at $55,000 after acquiring an additional 1,662 shares during the period. Institutional investors and hedge funds own 97.71% of the company’s stock.

About Pediatrix Medical Group

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.